Literature DB >> 21373949

Inhibition of cysteine proteases in acute and chronic spinal cord injury.

Swapan K Ray1, Supriti Samantaray, Joshua A Smith, Denise D Matzelle, Arabinda Das, Naren L Banik.   

Abstract

Spinal cord injury (SCI) is a serious neurological disorder that debilitates mostly young people. Unfortunately, we still do not have suitable therapeutic agents for treatment of SCI and prevention of its devastating consequences. However, we have gained a good understanding of pathological mechanisms that cause neurodegeneration leading to paralysis or even death following SCI. Primary injury to the spinal cord initiates the secondary injury process that includes various deleterious factors for ultimate activation of different cysteine proteases for degradation of cellular key cytoskeleton and other crucial proteins for delayed death of neurons and glial cells at the site of SCI and its penumbra in different animal models. An important aspect of SCI is the increase in intracellular free Ca(2+) concentration within a short time of primary injury. Various studies in different laboratories demonstrate that the most important cysteine protease for neurodegeneration in SCI is calpain, which absolutely requires intracellular free Ca(2+) for its activation. Furthermore, other cysteine proteases, such as caspases and cathepsin B also make a contribution to neurodegeneration in SCI. Therefore, inhibition of cysteine proteases is an important goal in prevention of neurodegeneration in SCI. Studies showed that individual inhibitors of cysteine proteases provided significant neuroprotection in animal models of SCI. Recent studies suggest that physiological hormones, such as estrogen and melatonin, can be successfully used for prevention of neurodegeneration and preservation of motor function in acute SCI as well as in chronic SCI in rats.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21373949      PMCID: PMC3101838          DOI: 10.1007/s13311-011-0037-1

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  84 in total

1.  Cathepsin B-dependent motor neuron death after nerve injury in the adult mouse.

Authors:  Li Sun; Zhou Wu; Masashi Baba; Christoph Peters; Yasuo Uchiyama; Hiroshi Nakanishi
Journal:  Biochem Biophys Res Commun       Date:  2010-07-29       Impact factor: 3.575

2.  Synergistic effect of melatonin on exercise-induced neuronal reconstruction and functional recovery in a spinal cord injury animal model.

Authors:  Kanghui Park; Youngjeon Lee; Sookyoung Park; Seunghoon Lee; Yunkyung Hong; Sang- Kil Lee; Yonggeun Hong
Journal:  J Pineal Res       Date:  2010-03-04       Impact factor: 13.007

Review 3.  Physiological low dose of estrogen-protected neurons in experimental spinal cord injury.

Authors:  Supriti Samantaray; Denise D Matzelle; Swapan K Ray; Naren L Banik
Journal:  Ann N Y Acad Sci       Date:  2010-06       Impact factor: 5.691

Review 4.  Neuroprotective efficacy of estrogen in experimental spinal cord injury in rats.

Authors:  Supriti Samantaray; Eric A Sribnick; Arabinda Das; Nakul P Thakore; Denise Matzelle; Shan P Yu; Swapan K Ray; Ling Wei; Naren L Banik
Journal:  Ann N Y Acad Sci       Date:  2010-06       Impact factor: 5.691

5.  Effect of endogenous androgens on 17beta-estradiol-mediated protection after spinal cord injury in male rats.

Authors:  Supatra Kachadroka; Alicia M Hall; Tracy L Niedzielko; Sukumal Chongthammakun; Candace L Floyd
Journal:  J Neurotrauma       Date:  2010-03       Impact factor: 5.269

6.  The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity involves membrane melatonin receptors.

Authors:  Arabinda Das; Misty McDowell; Matthew J Pava; Joshua A Smith; Russel J Reiter; John J Woodward; Abhay K Varma; Swapan K Ray; Naren L Banik
Journal:  J Pineal Res       Date:  2010-01-17       Impact factor: 13.007

Review 7.  Therapeutic potential of melatonin in traumatic central nervous system injury.

Authors:  Supriti Samantaray; Arabinda Das; Nakul P Thakore; Denise D Matzelle; Russel J Reiter; Swapan K Ray; Naren L Banik
Journal:  J Pineal Res       Date:  2009-07-13       Impact factor: 13.007

8.  Postinjury estrogen treatment of chronic spinal cord injury improves locomotor function in rats.

Authors:  Eric A Sribnick; Supriti Samantaray; Arabinda Das; Joshua Smith; D Denise Matzelle; Swapan K Ray; Naren L Banik
Journal:  J Neurosci Res       Date:  2010-06       Impact factor: 4.164

9.  Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury.

Authors:  Guido C Koopmans; Ronald Deumens; Armin Buss; Liam Geoghegan; Aye Mu Myint; Wiel H H Honig; Nadine Kern; Elbert A Joosten; Johannes Noth; Gary A Brook
Journal:  Exp Neurol       Date:  2009-04       Impact factor: 5.330

10.  Pharmacological evidence for a role of peroxynitrite in the pathophysiology of spinal cord injury.

Authors:  Yiqin Xiong; Edward D Hall
Journal:  Exp Neurol       Date:  2008-12-11       Impact factor: 5.330

View more
  25 in total

1.  Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.

Authors:  Maja Radulovic; Hyesook Yoon; Nadya Larson; Jianmin Wu; Rachel Linbo; Joshua E Burda; Eleftherios P Diamandis; Sachiko I Blaber; Michael Blaber; Michael G Fehlings; Isobel A Scarisbrick
Journal:  J Neuropathol Exp Neurol       Date:  2013-11       Impact factor: 3.685

2.  Gel-based protease proteomics for identifying the novel calpain substrates in dopaminergic neuronal cell.

Authors:  Chiho Kim; Nuri Yun; Young Mook Lee; Jae Y Jeong; Jeong Y Baek; Hwa Young Song; Chung Ju; Moussa B H Youdim; Byung K Jin; Won-Ki Kim; Young J Oh
Journal:  J Biol Chem       Date:  2013-11-14       Impact factor: 5.157

3.  Neurotherapeutics. Editorial.

Authors:  Edward D Hall; Stephen M Onifer
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

4.  Molecular Changes in Sub-lesional Muscle Following Acute Phase of Spinal Cord Injury.

Authors:  Nakul P Thakore; Supriti Samantaray; Sookyoung Park; Kenkichi Nozaki; Joshua A Smith; April Cox; James Krause; Naren L Banik
Journal:  Neurochem Res       Date:  2015-08-20       Impact factor: 3.996

Review 5.  Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration.

Authors:  Rory D Spence; Rhonda R Voskuhl
Journal:  Front Neuroendocrinol       Date:  2011-12-24       Impact factor: 8.606

Review 6.  LPS Preconditioning Attenuates Apoptosis Mechanism by Inhibiting NF-κB and Caspase-3 Activity: TLR4 Pre-activation in the Signaling Pathway of LPS-Induced Neuroprotection.

Authors:  Pushpa Gandi Sangaran; Zaridatul Aini Ibrahim; Zamri Chik; Zahurin Mohamed; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2021-01-09       Impact factor: 5.590

7.  Chronic intermittent ethanol induced axon and myelin degeneration is attenuated by calpain inhibition.

Authors:  Supriti Samantaray; Varduhi H Knaryan; Kaushal S Patel; Patrick J Mulholland; Howard C Becker; Naren L Banik
Journal:  Brain Res       Date:  2015-06-20       Impact factor: 3.252

Review 8.  Neurotrauma and mesenchymal stem cells treatment: From experimental studies to clinical trials.

Authors:  Ana Maria Blanco Martinez; Camila de Oliveira Goulart; Bruna Dos Santos Ramalho; Júlia Teixeira Oliveira; Fernanda Martins Almeida
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

Review 9.  Role of calpains in the injury-induced dysfunction and degeneration of the mammalian axon.

Authors:  Marek Ma
Journal:  Neurobiol Dis       Date:  2013-08-19       Impact factor: 5.996

10.  Administration of low dose estrogen attenuates persistent inflammation, promotes angiogenesis, and improves locomotor function following chronic spinal cord injury in rats.

Authors:  Supriti Samantaray; Arabinda Das; Denise C Matzelle; Shan P Yu; Ling Wei; Abhay Varma; Swapan K Ray; Naren L Banik
Journal:  J Neurochem       Date:  2016-04-12       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.